AbbVie: The Only Big Pharma Stock I'd Consider a Buy?and?Never?Sell

2026-03-04 09:00:00 ET

There were times when investors may have worried about hanging onto AbbVie (NYSE: ABBV) stock.

A decade ago, more than 63% of the pharmaceutical giant's revenue was tied up in one drug -- Humira. Granted, it was the top-selling drug in the world at the time. But despite the 130 patents it received for Humira's various applications,  sales were eventually going to drop once its patent protection expired and it faced generic competition.

Image source: Getty Images.

Continue reading